Clinical-stage biopharmaceutical company Bionomics (ASX:BNO) has announced that all patients have completed their treatment phase in the MODULATE clinical trial.
The phase two trial involves the use of Bionomics' BNC105 in combination with Bristol Myers Squibb’s OPDIVO (nivolumab) in patients with metastatic colorectal cancer.
The trial sponsor is the Australasian Gastro-Intestinal Trials Group (AGITG). The organisation is expecting results will be ready in the second quarter of 2021. It said this is ahead of the previously announced timeline for topline data of early 2023.
The AGITG is conducting the MODULATE trial to evaluate new experimental approaches to immunotherapy treatment in colorectal cancer patients.
In one arm of the trial, it is investigating whether Bionomics’ vascular disrupting agent BNC105 and OPDIVO can be used to treat advanced colorectal cancer patients who have exhausted other treatment options.
A second group of patients are receiving OPDIVO in combination with a Signal Transduction Activator of Transcription (STAT3) inhibitor.
Dr Errol De Souza, executive chairman of Bionomics said, “We thank AGITG, the trial Sponsor, and the patients who participated in the study, and look forward to reporting the topline data in Q2 2021”.